Insilico Medicine Demonstrates AI-Powered Target Discovery for Rare Sinonasal Cancer in NPJ Precision Oncology

Summary

Collaborative Study with University of Chicago and Johns Hopkins University Establishes First Multi-Omic Map and Actionable AI Targets for Rare Head and Neck Malignancy CAMBRIDGE, Mass. — Aug 4, 2026 — Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the publication of a collaborative study in the journal npj Precision Oncology. The peer-reviewed paper demonstrates how advanced artificial intelligence combined with comprehensive multi-omic analysis can successfully identify promising therapeutic targets in one of the rarest and least understood forms of head and neck cancer. The study represents the first comprehensive molecular characterization of inverted papilloma-associated sinonasal squamous cell carcinoma (IP-SNSCC). Conducted with leading investigators from the University of Chicago and Johns Hopkins University, the research illustrates how AI-powered biological target discovery can generate actionable therapeutic hypotheses even when conventional research is constrained by small patient populations and scarce molecular data. By integrating whole-exome sequencing, RNA sequencing, mitochondrial DNA sequencing, and AI-driven target prioritization, the research team reconstructed the molecular evolution of disease progression while identifying potential therapeutic opportunities for future clinical investigation. "Rare cancers have historically suffered from limited molecular data and few opportunities for therapeutic discovery," said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine and co-corresponding author of the study. "By combining comprehensive multi-omic profiling with PandaOmics, we were able to generate actionable therapeutic hypotheses in a disease where conventional approaches have struggled. This study demonstrates how AI can accelerate the identification of novel biology and potential therapeutic targets, helping researchers move from molecular understanding toward translational opportunities—even in diseases that have received relatively little attention." By integrating whole-exome sequencing, RNA sequencing, mitochondrial DNA sequencing, and AI-driven target prioritization, the research team reconstructed the molecular evolution of disease progression while identifying potential therapeutic opportunities for future clinical investigation. "R…